logo-loader

ANGLE kicks off ovarian cancer study for Parsortix

Last updated: 08:12 19 Jul 2016 BST, First published: 08:04 19 Jul 2016 BST

Blood sample
Parsortix is designed to detect cancer cells circulating in blood.

ANGLE Plc (LON:AGL, OTCMKTS:ANPCY) has kicked of an ovarian cancer study in Europe, advancing its technology towards securing CE-mark approval.

The company’s novel medical device is designed to capture cancer cells in blood, and it is expected to improve detection and analysis of the disease, and as such help improve treatment.

In the European study patients will enrol through four cancer centres – the Medical University of Vienna, Charité-Universitätsmedizin Berlin, and two clinics in Berlin’s Vivantes Network for Health.

The first of 200 patients has now been recruited.

"It has been a huge effort to put this clinical study in place and we are now excited to see the study in progress,” said Andrew Newland, ANGLE founder and chief executive.

“The four participating centres are enthusiastic and committed and we look forward to the next stage of development of this important clinical application."

The study is targeting patients that have been diagnosed (through imaging) with a pelvic mass and are scheduled for surgery. Blood will be analysed by Angle’s Parsortix system to detect the presence or absence of ovarian CTCs (circulating tumour cells).

The study’s aim is to discriminate successfully between women with benign and malignant masses, to be confirmed by histopathological examination of the tissue post-surgery.

Angle noted that the speed of patient recruitment is not in its control, but said it aims to have the study completed by the end of 2016.

If it proves successful, Angle would be able to offer Parsortix to certain accredited European hospitals.

The company highlighted that the four centres conducting the trial are likely to be early adopters, and as such there is potential for early revenues.

Additionally, based on results from the study, the company could subsequently design a further study which once validated could allow it to meet CE mark requirements. At that point the product could be made available to all hospitals in Europe.

Angle added that it is also working on plans for a similar process in the United States.

ANGLE PLC present at the Proactive One2One Investor Conference - January 11th

In a comprehensive presentation at the Proactive One2One Investor Conference, ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO, Andrew Newland, and CFO, Ian Griffiths, detailed the company's innovative approach to cancer diagnosis and treatment. Newland emphasised ANGLE's breakthrough technology, the...

on 17/1/24